June 18, 2008
Roxane Laboratories, Inc. Announces the Launch of Ramipril Capsules
COLUMBUS, Ohio, June 18 /PRNewswire/ -- Roxane Laboratories, Inc. announced today the approval of its Abbreviated New Drug Application (ANDA) for Ramipril Capsules, 1.25mg, 2.5mg, 5mg and 10mg by the U.S. Food and Drug Administration. The 1.25mg, 2.5mg, 5mg and 10mg strengths will be available in various packaging configurations. Roxane Laboratories Ramipril Capsules are available for immediate shipment to wholesalers and pharmacies nationwide.
(Logo: http://www.newscom.com/cgi-bin/prnh/20070410/CLTU122LOGO )Roxane Laboratories' Ramipril Capsules are AB rated to ALTACE(R) (ramipril) Capsules. Annual sales of Ramipril Capsules, 1.25mg, 2.5mg, 5mg and 10mg are approximately $932 Million(1).
Roxane Laboratories' Ramipril capsules are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics.
Please refer to the full prescribing information for a list of the most commonly reported side effects.
Full prescribing information for Ramipril Capsules is available on the Roxane Laboratories website at http://www.roxane.com/ or upon request by calling Roxane Laboratories Technical Product Information at 1.800.962.8364.
About Roxane Laboratories, Inc.
Roxane Laboratories is located in Columbus, OH in a modern 500,000 square foot manufacturing and laboratory facility. The facility spans 70 acres and currently employs over 1,000 people. Currently, Roxane Laboratories markets over 75 medications in nearly 250 package sizes, focusing on an expanding line of Multisource pharmaceutical products including: bulk and unit-dose liquids and solids; coated, sustained-release and controlled-release tablets; nasal sprays, cytotoxics and CII narcotics.
Roxane Laboratories, Inc., is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.
About Boehringer Ingelheim
Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and approximately 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2007, Boehringer Ingelheim posted net sales of US $15.0 billion (10.9 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.
For more information on Boehringer Ingelheim, please visit http://us.boehringer-ingelheim.com/.
(1) IMS MAT dollar sales ending 03/2008
ALTACE(R) is a registered trademark of King Pharmaceuticals, Inc.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20070410/CLTU122LOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, [email protected]
Roxane Laboratories, Inc.
CONTACT: Jason Kurtz, for Roxane Laboratories, +1-440-201-3668,[email protected]
Web site: http://www.roxane.com/http://us.boehringer-ingelheim.com/